News

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology announces the results of a general meeting (“General Meeting) held at 11am today.

The General Meeting follows the company's announcement on 3 June 2024, of a conditional subscription for £2.6 million, which was subject to shareholder approval.

The Company is pleased to announce that all resolutions were duly passed.

For further information please contact:

Incanthera plc
www.incanthera.com

Tim McCarthy, Chairman
tim.mccarthy@incanthera.com
+44 (0) 7831 675747

Simon Ward, Chief Executive Officer
simon.ward@incanthera.com
+44 (0) 7747 625506

Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com
+44 (0) 7776 234600

Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner / Liam Murray / Ed Downes
+44 (0) 20 7213 0880

Broker:
Stanford Capital Partners Ltd
Patrick Claridge / Bob Pountney
+44 (0) 20 3650 3650/51

Notes to Editors

About Incanthera plc

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantheraplc